2016 News

October 3, 2016

Morphotek and Eurofarma Laboratorios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America
Read More

September 13, 2016

Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center to Study Immunosuppressive Effects of Tumor Shed Antigens to Improve Future Patient Therapies
Read More

April 18, 2016

Morphotek Announces Publication of Phase 3 Results From MORAb-003-004 Trial in Platinum-Sensitive Ovarian Cancer Patients
Read More

News & Events > News Archive > 2016 News